🟢 Cue Biopharma is trading 5% up in pre-market ahead of expected August 11 earnings report

Cue Biopharma is trading at $28.48, up +5.01% in pre-market, with investors potentially positioning ahead of the expected August 11 earnings report, where clinical updates are a key focus.

• No fresh company-specific announcement explaining the August 10 pre-market gain was found.
• The latest announcement was the August 3 CFO appointment and CUE-221 IND submission, updated August 7, but it predates this move.
• Broader futures are modestly higher, though market strength alone does not clearly explain the move.